Janux Therapeutics Inc [JANX] stock is trading at $25.5, up 6.65%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JANX shares have gain 5.50% over the last week, with a monthly amount glided 6.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on July 11, 2025, when Raymond James initiated its Outperform rating and assigned the stock a price target of $65. Previously, H.C. Wainwright reaffirmed its Buy rating on December 03, 2024, and elevated its price target to $70. On December 03, 2024, BTIG Research reiterated its Buy rating and revised its price target to $100 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $79 on November 22, 2024. UBS initiated its recommendation with a Buy and recommended $69 as its price target on October 24, 2024. Stifel started tracking with a Buy rating for this stock on September 06, 2024, and assigned it a price target of $70. In a note dated May 30, 2024, Scotiabank initiated an Sector Perform rating and provided a target price of $47 on this stock.
Janux Therapeutics Inc [JANX] stock has fluctuated between $22.48 and $71.71 over the past year. Currently, Wall Street analysts expect the stock to reach $60.67 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $25.5 at the most recent close of the market. An investor can expect a potential return of 137.92% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 9.34M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -12.17%, Pretax Profit Margin comes in at -8.33%, and Net Profit Margin reading is -8.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.09 and Total Capital is -0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Janux Therapeutics Inc’s Current Ratio is 58.47. Further, the Quick Ratio stands at 58.47, while the Cash Ratio is 4.21. Considering the valuation of this stock, the price to sales ratio is 161.56, the price to book ratio is 1.49.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on May 01 ’25 when 3333.0 shares were sold. Officer, ANDREW MEYER completed a deal on May 01 ’25 to buy 3333.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 3334.0 shares on Apr 21 ’25.
